A Phase 2/3 interventional study of aganirsen in Ischaemic Central Retinal Vein Occlusion and Neovascular Glaucoma, sponsored by Gene Signal SAS. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-31.
Sponsored by Gene Signal SAS · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG Study
The STRONG Study is a phase II/III prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre study of aganirsen antisense oligonucleotide, a topical treatment for iCRVO intended to prevent Neovascular Glaucoma (NVG). The study will evaluate the efficacy of two different doses of aganirsen formulated in an eye emulsion in avoiding new vessel formation by blocking the Insulin Receptor Substrate (IRS)-1. Eligible patients will be treated with aganirsen or placebo for a period of 24 weeks. They will also be invited to participate in sub-studies working on the analysis of gonioscopic images, detection of biomarkers for neovascular glaucoma and risk factors for ischaemic central retinal vein occlusion.
39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.
This study's planned enrollment of 333 is above the median of 40 across 32 interventional studies indexed under Glaucoma, Neovascular.
Browse Glaucoma, Neovascular studies →This is the only study on the registry with Gene Signal SAS as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects meeting all of the following criteria will be considered for enrolment to the trial:
Must be accompanied by 4 or more out of 6 following criteria:
Exclusion Criteria:
Subjects presenting 1 or more of the following criteria will not be enrolled in the trial:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
43µg daily, one drop of 0.86 mg/g emulsion (morning) + one drop of placebo (evening) daily
Drug: aganirsen
86µg daily, one drop of 0.86 mg/g emulsion twice daily (morning and evening)
Drug: aganirsen
one drop of placebo emulsion (morning) + one drop of placebo emulsion (evening) daily
Drug: aganirsen
aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
Also known as: GS-101
NVG component
Co-primary I: NVG component scored dichotomously (NVG=yes/NVG=no) where "yes" is development of NVI, NVA, NVD, and/or NVE, or rescue treatment; "no" otherwise
Time frame: Week 24
IOP component
Co-primary II: IOP component scored dichotomously (failure/success); "failure" is rise in IOP from baseline to week 24 of ≥ 20% to \> 21 or rescue treatment; "success" otherwise
Time frame: Week 24
Secondary NVG
The time to development of secondary NVG in the study eye up to week 24 (in case aganirsen does not totally inhibit but slows down the development of NVG).
Time frame: 24 weeks
Anterior segment neovascularisation
The time to development of anterior segment neovascularisation (NVI or NVA), NVD or NVE in the study eye, requiring PRP or cryotherapy up to week 24.
Time frame: 24 weeks
NVG Classification
NVG Classification at 24 weeks on a scale from 1 (non-NVG) to 6 (most advanced NVG) based on central reading of neovascularisation
Time frame: 24 weeks
Visual Acuity
The change from baseline in BCVA (EDTRS letter score) in the study eye to week 24.
Time frame: 24 weeks
Number of additional needed laser treatments and re-treatments in the study eye at up to week 24
Number of additional needed laser treatments and re-treatments in the study eye at up to week 24
Time frame: 24 weeks
Required intensity of laser spots of additional laser treatments and re-treatments in the study eye at up to week 24
Required intensity of laser spots of additional laser treatments and re-treatments in the study eye at up to week 24
Time frame: 24 weeks
Retinal non-perfusion area
The change from baseline in size of retinal non-perfusion areas in the study eye to week 24
Time frame: 24 weeks
Retinal Thickness
Absolute change from baseline in retinal thickness in the study eye, assessed by spectral domain optical coherence tomography (SD-OCT) at week 24
Time frame: 24 weeks
Quality of Life
The change from baseline in the NEI-VFQ-25 health questionnaire total score to week 24
Time frame: 24 weeks
Quality of Life on EQ-5D
The change from baseline in the EQ-5D health questionnaire score to week 24
Time frame: 24 weeks
Safety: Incidence of treatment-emergent Adverse Events
Incidence, causality and intensity of adverse events between the treatment arms
Time frame: 24 weeks
No study locations are listed for this record.
Plan to share: No
The record gives a start of Jan 2017, a primary completion of Jun 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GS 101